Vai al contenuto| Home page|

   Ti trovi in: HOME »Programmi, progetti e risultati »I progetti »FIRB - Fondo per gli Investimenti della Ricerca di Base »FIRB
INIZIO_TESTO_DA_INDICIZZARE

Fund for investing in fundamental research

italiano - inglese
Research Units
  • Universita' degli Studi di VERONA
    SCIENTIFICO E TECNOLOGICO , VERONA (VR)
  • Universita' degli Studi di PAVIA
    BIOCHIMICA , PAVIA (PV)
  • Universita' degli Studi del MOLISE
    SCIENZE ANIMALI, VEGETALI E DELL'AMBIENTE , CAMPOBASSO (CB)
  • Universita' degli Studi di UDINE
    MATEMATICA E INFORMATICA , UDINE (UD)
  • Universita' degli Studi di BARI
    BIOCHIMICA E BIOLOGIA MOLECOLARE , BARI (BA)
  • Universita' degli Studi di TORINO
    FISICA TEORICA , TORINO (TO)
  • Universita' degli Studi di MILANO
    SCIENZE FARMACOLOGICHE , MILANO (MI)
  • Universita' degli Studi di MILANO
    Fisiologia generale e chimica biologica , MILANO (MI)
  • Universita' degli Studi di NAPOLI "Federico II"
    CHIMICA , NAPOLI (NA)
Similar FIRB:
Scientific and education field classification
International Patent Classification
Geographical classification
Bibliografia
(1) Möller, C., Allen, M., Elings, V., Engel, A. and Müller, D.J. (1999) Tapping mode atomic force microscopy produces faithful high-resolution images of protein surfaces. Biophys. J. 77, 1050-1058
(2) Müller, D.J., Janovjak, H., Letho, T., Kuerschner, L. and Anderson, K. (2002) Observing structure, function and assembly of single proteins by AFM. Prog. Biophys. Mol. Biol. 79, 1-43.
(3) Carrion-Vasquez, M., Oberhauser, A. F., Fischer, T. E., Marszalek,P. E. Li, H. and Fernandez J. M. (2000) Mechanical design of proteins studied by single-molecule force spectroscopy and protein engineering. Prog. Biophys. Mol. Biol. 74, 63-91.
(4) Palmer, R. E., Pratontep, S. and Boyen, H.-G. (2003) Nanostructured surfaces from size-selected clusters. Nature Mat. 2, 443-448.New
(5) Dalvit, C., Ardini, E., Flocco, M., Fogliatto, G., Mongelli, N. and Veronesi, M. (2003). A general NMR method for rapid, efficient, and reliable biochemical screening. J. Am. Chem. Soc. 125, 14620-14625.
(6) Clote, P. and Backofen, R. (2002) Computational Molecular Biology: An Introduction. Wiley Series in Mathematical and Computational Biology. (John Wiley & Sons, New York).
(7) Friesner, R.A. (ed.) (2002) Computational Methods for Protein Folding, Advances in Chemical Physics, vol. 120 (John Wiley & Sons, New York).
(8) Abkevich, V. I., Gutin A. M. and Shaknovich, E. I. (1994) Free energy landscape for protein folding kinetics: Intermediates, traps, and multiple pathways in theory and lattice models simulations. J. Chem. Phys. 101, 6052-6062.
(9) Broglia , R. A. and Tiana, G. (2004) Lattice model of protein folding and of non-conventional drug design. J. Phys. Condens. Matter 16, R111-R144
(10) Betancourt, M.R. and Thirumalai, D. (1999) Pair potentials for protein folding: Choice of reference states and sensitivity of predicted native states to variations of interaction schemes. Protein Sci. 8, 361-369.
(11) Fogolari , F., Brigo, A. and Molinari, H. (2002) The Poisson-Boltzmann equation for biomolecular electrostatics: a tool for structural biology. J. Mol. Recognit. 15, 377-392.
(12) Akerstrom, B., Flower, D. and Salier , J.P., Lipocalins: Unity in diversity. Review. (2000) Biochim. Biophys. Acta 1482, 1-8.
(13) Urade, U. and Hayaishi, O. (2000). Prostaglandin D synthase: Structure and function. Vitam. Horm. 56, 89-120.
(14) Di Pietro, S.M., Córsico, B., Perduca, M., Monaco, H.L. and Santomè, J.A. (2003).Structural and biochemical characterization of toad liver fatty acid-binding protein. Biochemistry 42, 8192-8203.
(15) Peters, T. Jr. (1996) All about Albumin. Biochemistry, Genetics and Medical Applications. Acad. Press, San Diego.
(16) Sirtori, C.R., Calabresi, L. and Franceschini, G. (1999). Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 142, 29-40.
(17) Borhani, D.W., Rogers, D.P., Engler, J.A. and Brouillette, C.G. (1997). Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. USA 94, 12291-12296.
(18) Narayanaswami, V. and Ryan, R.O. (2000). Molecular basis of exchangeable apolipoprotein function. Biochim. Biophys. Acta 1483, 15-36.
(19) Yu, L-G, Fernig, D.G., Smith, J. A., Milton, J.D. and Rhodes, J. M. (1993). Reversible inhibition of proliferation of epithelial cell lines by Agaricus bisporus (edible mushroom) lectin. Cancer Res. 53, 4627-4632.
(20) Kilpatrick, D.C. (1999). Mechanisms and assessment of lectin-mediated mitogenesis. Mol. Biotechnol. 11, 55-65.
(21) Monzavi, R., and Cohen, P. (2002) IGFs and IGFBPs: Role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 16, 433-47.
(22) Furstenberger, G. and Senn, H.J. (2002) Insulin-like growth factors and cancer. Lancet Oncol. 3, 298-302.
(23) D'Alessio, G., Di Donato, A., Mazzarella, L., and Piccoli, R. (1997). Seminal ribonuclease: The importance of diversity in ribonucleases: Structures and functions (D'Alessio, G. & Riordan, J. F., pp. 383-423, Academic Press, New York, N.Y.).
(24) De Lorenzo, C., Nigro, A., Piccoli, R. and D'Alessio, G. (2002) . A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett. 516, 208-12.
(25) Frillingos, S., Sahin-toth, M., Wu, J. and Kaback, H.R. (1998). Cys scanning mutagenesis: A novel approach to structure-function relationship in polytopic membrane proteins. FASEB J. 12, 1281-1299.
(26) Guastella, J., Nelson, N., Nelson, H., Czyzykk, L., Keynan, S., Miedel, M.C., Davidson, N., Lester, H.A. and Kanner, B.I. (1990). Cloning and espression of a rat brain GABA transporter. Science. 249, 1303-1306.
(27) Castagna, M., Shayakul, C., Trotti, D., Sacchi, V.F., Harvey, W.R. and Hediger, M.A. (1998). Cloning and characterization of a potassium-coupled amino acid transporter. Proc. Natl. Acc. Sci. USA. 95, 5395-5400.
(28) Amer, R.E. (2000) Inhibitors of mammalian central nervous system selective amino acid transporters, Curr.Med.Chem. 7, 199-209.
(29) Temussi, P. A., Masino, L. and Pastore, A (2003). From Alzheimer to Huntington: Why is a structural understanding so difficult? EMBO J. 22, 355-361.
(30) Hashimoto, M., Rockenstein, E., Crews, L. and Masliah, E. (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases, Neuromolecular Med. 4, 21-36.
(31) Crescenzi, O., Tomaselli, S., Guerrini, R., Salvadori, S., D'Ursi, A. M., Temussi, P. A. and Picone, D. (2002). Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment: Similarity with a virus fusion domain. Eur. J. Biochem. 269, 5642-5648.
(32) Gulbins, E., Dreschers, S. and Bock, J. (2003) Role of mitochondria in apoptosis Exp. Physiol. 88, 85-90.
(33) Robert, J. and Jarry, C. (2003) Multidrugresistance reversal agents. J. Med. Chem., 46, 4805-4817.
(34) Belkin, M. and Schwartz, M. (1989) New biological phenomena associated with laser radiation. Health Phys. 56, 687-690.
(35) Bauer, S., Kemter, K., Bacher, A., Huber, R., Fischer, M. and Steinbacher, S. (2003) Crystal structure of S. pombe riboflavin kinase reveals a novel ATP and riboflavin-binding fold. J. Mol. Biol 326, 1463-1473.
(36) Gerdes ,S.Y., Scholle, M.D., D'Souza, M., Bernal, A. Baev, M.V., Farrell, M., Kurnasov, O.V., Daugherty, M.D., Mseeh, F., Polanuyer, B.M., Campbell, J.W., Anantha, S., Shatalin, K.Y., Chowdhury, S.A., Fonstein, M.Y. and Osterman A.L. (2002). From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184, 4555-72.
(37) Decker, K. and Brandsch, R. (1991). Flavoproteins with a covalent histidyl(N3)-8 alpha-riboflavin linkage. Biofactors 3, 69-81.
(38) Mewies, M., McIntire, W.S. and Scrutton, N.S. (1998) Covalent attachment of flavin adenin dinucleotide (FAD) and flavin mononucleotide (FMN) to enzymes: the current states of affairs. Prot. Sci. 7, 7-20.
Keywords
Atomic force microscopy (AFM); Protein crystallography; Biomolecular NMR; Molecular dynamics simulations; Biomolecular recognition; Protein structure-function relationships

Molecular recognition in protein-ligand, protein-protein and protein-surface interactions: development of integrated experimental and computational approaches to the study of systems of pharmaceutical interest.

Università degli Studi di Verona
Abstract
This research project is presented by 9 collaborating groups from 8 different Universities. The reason for bringing together such a large number of scientists is that it is hoped that, by assembling their different fields of expertise, a qualitatively different approach will become possible and the molecular recognition process problem will be tackled more successfully by all the groups involved.
Atomic force microscopy, X-ray Crystallography, NMR and other spectroscopic techniques, mass spectrometry, non-conventional electrophoresis, and amino acid sequencing will be used to characterize at the molecular level and with the highest possible degree of detail a series of proteins of pharmaceutical interest. Particular relevance will also be given to the development and application of new computational methods that will be applied to the systems under experimental study in our laboratories. The molecules we have selected have been chosen because they are potential targets for drug design. We thus intend to work on the establishment of a solid scientific base that can be the starting ground for the successful development of new molecules of pharmaceutical relevance. A reasonable number of different proteins will be investigated from a structural point of view by as many of the 9 different teams (operating units) as feasible. Their interactions with ligands natural and synthetic, will also receive much attention and ultimately software will be developed to predict in>>>

Principal Investigator
Ugo Luigi MONACO, Universita' degli Studi di VERONA
Research Goal
The main goals of this research program are the following:
a) The creation of an integrated research team, geografically localized in different areas of our country and with important collaborations with well known international centres of research. In this way, the 9 participating units will share their different methodological know-how that ranges from genomics to the most advanced computationl methods.
b) Progress in the final common goal of all the units which is to understand and to be able to predict the behaviour of proteins with very different structural and functional complexity, all very promising as targets for drug design.
And last but not least, a third goal is
c) To guarantee an adequate scientific training through their participation in the activities proposed, of as many Ph.D. students and Post Docs as is compatible with the research undertaken.
The techniques available to the group are those most prominent in the modern structural analysis of biological macromolecules: atomic force microscopy, X-ray crystallography, NMR, U.V. and visible spectroscopy, mass spectrometry, epitope mapping and other immunological methods advanced electrophoretic and conventional chemical sequencing procedures as well as very powerful computational methods. The proteins, selected on the basis of their relevance as potential targets for drug design are, in every case, under active investigation in at least one of our laboratories.
If this>>>

Timescale
36 months